Optimization of an Ultra-High-Throughput Screening Assay for D-Allulose 3-Epimerase Protein Engineering

A slow enzyme kills productivity

The bottleneck in allulose production is often the enzyme. DAEase, or D-allulose 3-epimerase, converts D-fructose into D-allulose. That reaction makes the low-calorie sugar possible. But many natural DAEase variants cannot handle industrial heat for long. The result is high enzyme loading, short reaction runs, and higher costs per kilogram. This paper addresses that problem head-on by optimizing the screening process used to engineer better DAEase variants.

Background: Why DAEase needs better screening

D-Allulose is the C-3 epimer of D-fructose. It tastes and sweetens like sucrose, which makes it attractive for formulators. The challenge is production. You need an enzyme that performs well at elevated temperatures and stays active long enough to be economical.

Directed evolution can create such enzymes, but only if you can find the rare beneficial mutations. Traditional screening methods are slow. You can test hundreds or thousands of variants, but not millions. The researchers behind this study optimized a PsiR-based ultra-high-throughput screening system. That system lets them sort through large mutant libraries quickly and identify DAEase variants with better specific activity and thermostability.

What the study did

The team optimized the PsiR-based screening assay specifically for DAEase directed evolution. Using that method, they isolated the single mutant I228V. This variant already showed improved specific activity and thermostability compared to wild-type DAEase.

They then added two more mutations: D281G and C289R. The resulting triple mutant, I228V/D281G/C289R, became the main focus. The data are striking.

Key findings at a glance

Variant	Specific activity	Half-life at 60°C	D-Fructose conversion at 70°C
Wild-type DAEase	Baseline	Baseline	21.64%
I228V/D281G/C289R	1.42x wild-type	62.97x longer	28.11%

That half-life jump matters. A 62.97-fold increase at 60°C means the enzyme stays active far longer under heat stress. The specific activity gain of 1.42x is also meaningful. You need less enzyme to convert the same amount of fructose.

In the biosynthesis experiment at 70°C, the triple mutant converted 28.11% of D-fructose, compared to 21.64% for wild-type. That is roughly 30% higher conversion in the same conditions. For a producer, that difference can shift the economics.

What this means for manufacturers

This paper is not a commercial product announcement. It is a research result. But it points to a practical future.

First, longer enzyme half-life means lower enzyme consumption. If a DAEase variant survives for hours instead of minutes, you can reduce enzyme loading or run longer cycles. Both cut cost.

Second, higher specific activity improves productivity. A 1.42x specific activity gain means more product per unit of enzyme over the same time. That helps in batch and continuous systems.

Third, the thermostability gain gives formulators more freedom. The triple mutant held up at 70°C in the biosynthesis test. That is a demanding temperature. Many current processes will want that kind of durability, especially if you are considering high-temperature reactions to improve substrate solubility or reduce viscosity.

There is a catch, though. The study used optimized laboratory conditions. You should test any engineered enzyme in your own substrate streams. Syrup purity, pH, and co-solutes all affect enzyme performance. A variant that shines in a clean lab buffer may behave differently in a corn or cane syrup matrix.

Common questions formulators ask

Does the triple mutant work with real industrial fructose syrup? The study did not test commercial syrups. It used defined D-fructose substrate. The conversion results are promising, but pilot testing is required.

Is the 62.97x half-life improvement real at production scale? That number comes from controlled 60°C incubations. Scale-up can introduce factors like shear stress and impurities. Still, a half-life improvement of this size rarely disappears entirely. Expect meaningful gains.

Should I delay enzyme sourcing until this variant is commercialized? No. Keep evaluating current suppliers. This is one paper, not a registered enzyme product. Use it as evidence that the field is moving fast. Hold suppliers to higher thermostability and activity standards.

The next generation of allulose enzymes is coming

Screening speed changes everything. With ultra-high-throughput methods like the PsiR-based assay, researchers can test millions of DAEase variants instead of a few thousand. That accelerates the path from lab hit to industrial enzyme.

The I228V/D281G/C289R mutant is a good example. Three mutations produced a meaningful lift in activity, thermostability, and conversion. Future variants may do even better. For ingredient buyers, that means better enzyme options are likely on the way. For formulators, it means process economics should keep improving. The enzyme is no longer the weakest link.